$CBLL

Chao Xingjuan sold $841K of CBLL

Chao Xingjuan (President and CEO) sold 33,614 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.84M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chao Xingjuan
Published Aug 20, 2026, 10:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CBLL
Neutral
medium confidence
Mentioned
$CBLL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

Provides fresh data on insider holdings; modest sell‑off may be interpreted by short‑term traders.

02

Market read

New insider sale information for CBLL, modest in size, limited trading relevance.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CBLLNeutralMedium confidence
Context

President and CEO Chao Xingjuan sold 33,614 shares for $841,292.45 via a 10b5-1 plan, reducing his stake to 787,799 shares.

Expected impact

Potential slight downward pressure, likely limited to a few basis points.

Evidence & confidence

Sale amount is under $1M and follows a pre‑arranged plan, reducing actionable significance.

Market effects

Minimal impact on the medical‑device sector; insider activity is routine.

No regional effect beyond Ceribell shareholders.

Limited to investors tracking insider transactions.

Counterpoint

The sale could be unrelated to company outlook, merely portfolio rebalancing.

Key entities

  • Ceribell, Inc.

    Medical‑device firm developing seizure detection technology.

  • Chao Xingjuan

    President and CEO of Ceribell.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor